Company: MIRA
Filing Date: 2025-06-30
Form Type: 8-K
Source: 0001641172-25-017046
Chunk: 1

Company: MIRA PHARMACEUTICALS, INC.
Filing Date: 2025-06-30
Form: 8-K
Item: Item 8.01
Chunk 1
---
 desire to seek out and consume nicotine. Treated animals were less willing to pursue nicotine even in stressful
conditions, and they no longer showed a preference for environments linked to nicotine rewards. At the high dose, their behavior matched
that of healthy animals with no nicotine craving.

Neurohormonal
Balance:

Obese
animals had extremely high levels of leptin (a hunger-regulating hormone) and unusually low levels of ghrelin (the ‘hunger signal’).
This imbalance often leads to constant hunger and poor appetite control. SKNY-1 normalized both hormones, improving the body’s
ability to regulate hunger and energy use.

Brain
Dopamine Regulation:

Obese
animals had too much dopamine in the brain, likely tied to increased reward and cravings. SKNY-1 reduced these dopamine levels - but
only at the lower dose. The high dose did not affect dopamine, suggesting the drug can reduce craving without overstimulating the brain.

The
Company believes these findings further support the advancement of SKNY-1 toward Investigational New Drug (IND)-enabling studies. With
obesity and smoking representing two of the leading causes of preventable death - and a combined global market opportunity exceeding
$200 billion - MIRA intends to prioritize SKNY-1 as a potential cornerstone asset pending completion of the acquisition of SKNY Pharmaceuticals,
Inc.

SIGNATURES

Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.

                     MIRA                                          
  Dated:             By:                        /s/                
                     Name:                      Erez               
                     Title:                     Chief